Clinical trials: Malaria,Falciparum
Malaria
Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers
In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual parasites in asymptomatic carriers…
- Trial name
- PRINOGAM (NCT01838902)
- Testing
- DHA-PPQ, PQ (0.75), PQ (0.4)
- Where
- The Gambia
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Falciparum Infection
rCSP/AP10-602 [GLA-LSQ] Vaccine Trial
This is a study to evaluate the safety, immunogenicity, and efficacy of a recombinant circumsporozoite protein (rCSP) malaria vaccine administered with and without AP 10-602 [Glucopyranosyl Lipid A (GLA) in liposome Quillaja…
- Trial name
- NCT03589794
- Testing
- AP10-602, Malaria challenge, rCSP
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Testing, Performance
Validation of INSPiRED Innovative Smart Diagnostic Devices for the Detection of Parasites Infections.
Malaria, schistosomiasis and ancylostomiasis are three parasitic diseases which affect hundreds of millions of people and are an important cause of global mortality and morbidity.
- Conditions
- Testing, Performance, Specificity, Sensitivity
- Trial name
- INSPiRED-WP3 (NCT04505046)
- Where
- Gabon
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Malaria
Apheresis to Obtain Plasma and White Blood Cells in Malies
Background: Some clinical trials require larger amounts of plasma and white blood cells than can be collected through simple blood donations.
- Trial name
- NCT01511601
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria,Falciparum
A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI
USSPZV7 is a randomized, phase 1, double-blind, placebo-controlled trial of Sanaria® PfSPZ Vaccine administered on Days 1, 8 and 29 by direct venous inoculation (DVI) to assess safety, tolerability, immunogenicity, and vaccine…
- Trial name
- NCT05604521
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum
This was a randomised, double-blind, placebo-controlled study to compare the efficacy of a range four weekly doses of tafenoquine, and weekly mefloquine, with placebo as chemosuppression of P. falciparum malaria.
- Trial name
- NCT02488902
- Testing
- Tafenoquine 25mg, Tafenoquine 50mg, Tafenoquine 100 mg
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria,Falciparum
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
A phase Ib age de-escalation and dose escalation open label clinical trial of the safety, immunogenicity and ex-vivo efficacy of a candidate malaria vaccine Pfs25-IMX313/Matrix-M administered intramuscularly in healthy adults and…
- Trial name
- NCT04271306
- Testing
- Pfs25-IMX313 (10ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug), Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)
- Where
- Tanzania
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria
Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.
- Trial name
- NCT00344006
- Testing
- chlorproguanil-dapsone-artesunate, artemether-lumefantrine
- Where
- 9 sites in Burkina Faso, Ghana and 3 more
- Volunteers
- 1,395 people
- Sponsor
- GlaxoSmithKline
Plasmodium Falciparum Malaria
Artemisinin-resistant Malaria in Cambodia
Background: Artemisinin-based combination therapies (ACTs) are the first-line treatments for malaria. ACTs are highly effective, but malaria caused by the Plasmodium falciparum parasite is becoming resistant to some ACTs.
- Trial name
- NCT01736319
- Where
- Cambodia
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Malaria
Mass Screening and Treatment for Reduction of Falciparum Malaria
In this project, the investigators aim at an operational research deployment of Ultrasensitive Rapid Diagnostic Test (URDT) -based Mass Screening and Treatment (MSAT) in the Malaria Elimination Task Force (METF) elimination…
- Trial name
- MSAT (NCT04093765)
- Testing
- Ultrasensitive Rapid Diagnostic Test (URDT), Antimalarials
- Where
- Thailand
- Volunteers
- 5,542 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Falciparum
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
The purpose of this study is to compare the safety and efficacy in children aged 6 - 59 months with uncomplicated malaria, treated with either conventional artemether/lumefantrine tablets(Coartem®) or artemether/ lumefantrine…
- Trial name
- NCT00529867
- Testing
- Artemether/lumefantrine tablets, Artemether/Lumefantrine suspension
- Where
- Kenya
- Volunteers
- 267 people
- Sponsor
- Dafra Pharma
Falciparum Malaria
Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine (80%) and more recently an increasing degree of resistance to sulfadoxine-pyrimethamine monotherapy (12%).
- Trial name
- ASPF (NCT01115439)
- Testing
- artesunate plus sulfadoxine-pyrimethamine (AS+SP)
- Where
- 4 sites in Afghanistan
- Volunteers
- 100 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Malaria in Early Life Study
The purpose of this study is to assess the effectiveness of different malaria control strategies in the first year of life. The effectiveness of delivering an intermittent screening and treatment programme with…
- Trial name
- NCT02001428
- Testing
- dihydroartemisinin-piperaquine
- Where
- Indonesia
- Volunteers
- 757 people
- Sponsor
- Gadjah Mada University
Uncomplicated Malaria, Asymptomatic Condition
A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
Malaria is caused by protozoan parasites of the genus Plasmodium and it is the most important parasitic disease in terms of mortality and morbidity.
- Conditions
- Uncomplicated Malaria, Asymptomatic Condition, Falciparum Malaria
- Trial name
- ZYFER-1 (NCT05911828)
- Testing
- ZY19489 + Ferroquine (FQ)
- Where
- Gabon
- Volunteers
- 36 people
- Sponsor
- Zydus Lifesciences Limited
Malaria, Malaria, Falciparum
Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P.
- Trial name
- NCT02329301
- Testing
- MDA with DHAp (Eurartesim), Focal MDA with DHAp (Eurartesim)
- Where
- Zambia
- Volunteers
- 2,430 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults.
- Trial name
- NCT01024686
- Testing
- p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Malaria
Prevalence Survey of Antimalarial Drug Resistance Markers
Study is cross-sectional and observational with one-time dried-blood spot sample collection from persons with laboratory-confirmed uncomplicated Plasmodium falciparum malaria (mixed or monoinfection).
- Trial name
- NCT03217851
- Testing
- Blood Collection, Dried Blood Spot
- Where
- Thailand
- Volunteers
- 4,000 people
- Sponsor
- University of Oxford
Plasmodium Falciparum Malaria, Pregnancy Malaria
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Malaria during pregnancy remains an important public health issue in endemic countries. Most cases of malaria in pregnant women are asymptomatic, and can contribute to adverse outcomes, such as maternal and neonatal anaemia as…
- Conditions
- Plasmodium Falciparum Malaria, Pregnancy Malaria, Diagnoses Disease
- Trial name
- NCT03462615
- Testing
- HS-RDT
- Where
- Papua New Guinea
- Volunteers
- 930 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Malaria
Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model
This was a single centre, randomised, double-blind, placebo-controlled Phase Ib study, to evaluate the safety, tolerability and chemoprotective activity of P218 in a controlled P. falciparum sporozoite infection model.
- Trial name
- NCT03707041
- Testing
- P218 (1000 mg) Oral Capsules, P218 (100 mg) Oral Capsules, PfSPZ Challenge
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Healthy
DSM265 Prophylaxis of Plasmodium Falciparum Malaria
The study is a single centre, randomised, placebo-controlled, double-blind study with DSM265 including up to two cohorts of healthy male and female volunteers aged 18 to 45 years.
- Trial name
- NCT02562872
- Testing
- DSM265, Sporozoites, Infective mosquito bite
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture